Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyaf437 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Xubiao Wei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Radiosurgery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, San Hang Program of Navy Medical University (2025), Project of Shanghai Municipal Science and Technology Commission.
Abstract (Originalsprache)
Background
Radiotherapy (RT) provides meaningful local control for hepatocellular carcinoma (HCC) but is limited by radio-resistance. Preclinical and clinical data suggest that adding programmed death receptor-1 (PD-1) blockade may enhance radiosensitivity in various malignancies. We compared outcomes of stereotactic body radiotherapy (SBRT) plus PD-1 inhibitors vs SBRT alone in unresectable HCC.
Methods
We retrospectively analyzed consecutive patients treated with SBRT (January 2019-December 2024) from 3 centers. Key exclusions removed confounding from recent systemic/locoregional therapies. Propensity score matching (PSM, 1:1) balanced demographics, liver function, tumor characteristics, and prior therapy. Tumor responses were assessed by RECIST 1.1, while survival was estimated by Kaplan–Meier and Cox models.
Results
Of 540 eligible patients, 157 received RT+PD-1 and 383 received RT alone; after PSM, 314 patients remained (157/157). Median follow-up was 29.9 months (IQR 21-36). After matching, RT+PD-1 showed a higher objective response rate (ORR) that approached significance (48.4% vs 37.6%, P = .053). Progression-free survival (PFS) was significantly prolonged with RT+PD-1 (median 11.0 vs 8.5 months; 1-year 69.9% vs 54.1%; HR 0.75, 95% CI 0.58-0.96, P = .024). OS also favored RT+PD-1 (median 33.9 vs 26.3 months; 3-year 41.9% vs 23.0%; HR 0.74, 95% CI 0.54-1.02, P = .066). On multivariable analysis after PSM, RT+PD-1 independently reduced risks of progression (HR 0.69, P = .005) and death (HR 0.70, P = .029). Adverse events (AEs) were similar overall, but grade ≥3 AEs were more frequent with RT+PD-1 (15.2% vs 7.0%, P = .020).
Conclusions
In unresectable HCC, adding PD-1 blockade to SBRT enhances anti-tumor activity and improves long-term survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200433, China.
- Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200433, China.
- Department of Ultrasound, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200082, China.
- Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, Sichuan 610041, China.
- School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou 215000, China.
ORCID-Profile: Shuqun Cheng
Förderung
- National Key R&D Program of China
- San Hang Program of Navy Medical University (2025)
- Project of Shanghai Municipal Science and Technology Commission
Zitieren
APA
Wei, X., Jiang, Y., Li, Y., Shi, H., Guo, W., Shi, J., Zeng, Z., Wen, T., Jiao, Y., Wang, M., & Cheng, S. (2026). Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf437
Vancouver
Wei X, Jiang Y, Li Y, Shi H, Guo W, Shi J, et al. Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study. The Oncologist. 2026. doi:10.1093/oncolo/oyaf437
BibTeX
@article{Wei2026,
author = {Wei, Xubiao and Jiang, Yabo and Li, Yong and Shi, Hong and Guo, Weixing and Shi, Jie and Zeng, Zhaochong and Wen, Tianfu and Jiao, Yang and Wang, Miaomiao and Cheng, Shuqun},
title = {Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyaf437}
}
EUVIMED